CSL CEO calls on industry to improve patients' access to medicines

14 March 2018
2019_biotech_test_vial_discovery_big

In a keynote address on patients' access to medicines at the eyeforpharma Barcelona summit, chief executive and managing director of Australia’s CSL Limited (ASX: CSL) Paul Perreault told fellow biotech industry leaders that access to life-saving medicines remains a global challenge that cannot be ignored.

"Our role in ensuring patients have access to these medicines is an imperative, not an afterthought. As an industry, we must be a reliable and engaged partner in understanding and overcoming barriers to access," said Mr Perreault.

Global barriers to patient access include regulatory delays of approving new therapies, reimbursement challenges and supply disruptions. In addition, Mr Perreault emphasized the importance of promoting early diagnosis and treatment of conditions to give patients the best opportunity to effectively manage their illnesses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology